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Immunology Aspects in Tension-Type Headache Chronicity 
Restu Susanti1 





Tension-Type Headache (TTH) headache is a type of primary headache which mostly 
complained by patients. The pain often ignored due to low mortality rates. Inadequate 
management makes the pain becoming chronic and causing a high disability rate. Many factors 
involved in transforming infrequent tension-type headache to chronic tension-type headache. 
A deeper understanding of the immune system's role in the pathophysiological process and 
modulation of chronic pain could be a potential target for developing therapies in managing 
chronic pain. 













brought to you by COREView metadata, citation and similar papers at core.ac.uk






 Tension-type headache (TTH) headache is a primary headache often complained of by 
all age groups with an incidence of 42% of all types of primary headache1-4.  Nearly 90% of 
young adults have experienced one headache attack every month, 18-37% experience several 
monthly attacks, and 2-3% of patients become chronic TTH4-7. Based on gender, TTH is 1.5 
times more common in women than men8. 
 Tension-type headache (TTH) is the most common health problem in the world2-4. It's 
caused by ignorance of the pain and self-medication attempts by TTH sufferers, which make it 
tends to become chronic and cause disability2,9-11. Reportedly 60% of TTH sufferers have 
decreased ability to work, increased absence rates followed by a decrease in the quality of life 
(both physical and psychosocial), which have a significant socio-economic impact. 
 The differentiation of TTH is based not only on the frequency of attacks but also on the 
different underlying pathophysiology.11 The pathogenesis of TTH currently focused on the role 
of muscle tissue and the process of pain proprioception. It has been suggested that the role of 
muscle components contributes to the pain sensitization process associated with the changes in 
TTH from acute to chronic. 13,14 
Abnormalities in peripheral and central nociceptive systems combined with 
environmental, emotional, and genetic factors play a role in the pathophysiology of TTH. 
Allegedly in the episodic form, the peripheral mechanism is more dominant, whereas in the 
chronic type, in addition to the peripheral mechanism, central sensitization has occurred.5,6,10,11 
It is essential to understand the pathophysiological mechanisms underlying the 
transformation of acute TTH into chronic from immunological and biomolecular aspects, 
which could be a consideration in pain management and chronic pain prevention. Later it will 
help the clinician to treat the headache appropriately, decrease patients' complaints, and 
increase patients' productivity. 
 
Definition And Clinical Description 
Tension-type headache (TTH) headache is a primary headache characterized by 
headaches lasting from 30 minutes to 7 days which meet the criteria: bilateral location, pressing 
or binding (not throbbing) nature, mild or moderate intensity, not exacerbated by routine 




photophobia or phonophobia.12,15 Clinical manifestations of TTH can also be accompanied by 
pericranial tenderness during manual palpation2. 
Tension-type headache (TTH) is distinguished based on the attack episodes7. According 
to the International Headache Society Classification the Third Edition the Beta Version (ICHD-
3 beta version). For infrequent episodic TTH there are at least 10 attack episodes with an 
average of <1 day/month (<12 days/year). For frequent episodic TTH there are at least 10 
episodes of attack in 1-15 days/month for at least 3 months (12-180 days/year) and in chronic 
TTH headache occurs ≥ 15 days/month or lasts > 3 months (≥180 day/year).10,15 
 
Myofascial Trigger Points in Chronic Tension-Type Headache 
Chronic Tension-Type Headache (CTTH) is associated with active Trigger Points (TrPs) 
located in the muscles supplied by the C1-C3 segments (upper trapezius, lower trapezius, 
suboccipital, sternocleidomastoid) and by trigeminal nerves (temporalis, masseter, 
extraocular).16,17 
During the headache phase, muscle pain increases and the threshold of thermal pain 
decreases in the temporal region. Pain hypersensitivity is found in those experiencing tension-
type pain, with greater disturbances in individuals with chronic or more frequent headaches, 
implying that central sensitization can contribute to the synchronization of headaches.18 
Under normal condition, myofascial pain mediated by thin myelinated fibers (Aδ) and 
nonmyelinated C fibers. Thick myelinated fibers (Aα and Aß) normally mediate harmless 
sensations. Whereas in abnormal circumstances, such as mechanical stimuli, ischemia, and 
chemical mediators, can excite and sensitize Aδ fibers and C fibers, therefore have a role in 
increasing tenderness in TTH.19 
Prolonged input of the nociceptors from the pericranial myofascial tissue will cause 
central sensitization in second and third-order neurons (dorsal horn of spinal cord at the upper 
cervical and trigeminal levels, as well as the thalamus and somatosensory cortex). Patients with 
chronic TTH are hypersensitive to various cephalic and extracephalic stimuli, not limited to 
the location of symptoms. It is a strong indication of a central sensitization process because the 
hypersensitivity in peripheral sensitization is limited to a particular location. 
The theory underlying chronic TTH is central sensitization process due to prolonged 
peripheral nociceptive input from muscle tissue. Trigger points actively induce chemical 




norepinephrine), not only at the site of pain but also in areas of pain-free distant (referred pain). 
9,17 
 
Immunology Aspects in Tension-Types Headache 
There is not much research on the role of immunology in the chronicity of tension-type 
headaches. Verdova in 2017 found levels of Interleukin-1 β increased in chronic TTH. Aldy S 
Rambe in 2017 found levels of alpha TNF, IL-1 and IL-6 increased in chronic TTH. 
Amitriptyline and dexketoprofen are associated with a decrease in the value of the Numeric 
Rating Scale (NRS) in chronic TTH but not related to TNF levels of alpha, IL 1 and IL 6 levels. 
20,21 
 
a. Peripheral Sensitization 
After nociceptor stimulation, mast cell degranulation occurs. Interleukin 5 (IL-5), 
serotonin (5-HT), histamine, and nerve growth factor (NGF) are also released. They will bind 
with IL-5R, 5-HT2, histamine 2 (H2) receptors, and TrkA which causes pain sensitivity. In 
addition, mast cells also excrete Tumor Necrosis Factor Alpha (TNFα), IL-1β and IL-6. The 
activation of TNFα receptor 1 (TNFR1) will cause phosphorylation of the Nav1.9 channel2,23. 
The release of mediators by immune cells in the peripheral sensitization process is described 
in Figure 1. 
 
Figure 1. Immune Cells Release Mediators in the Peripheral Sensitization Process in Nociceptors22 
 
The activation of IL-1 receptor 1 (IL-1R1) increases the expression of TRPV1. The IL-6 
binds with gp130 and increases the expression of TRPV1 and TRPA1. They later will increase 
the neuron response to heat and chemicals which called sensitization22,23. Macrophages also 




receptors 1-4 (EP1-4). Th17 cells and γδT cells release IL-17RA. IL-17RA neuronal signaling 
will cause nociceptive neuron sensitivity.22 
Three examples of interactions between immune cells and nerve terminals are explained 
in figure 2: (1) Degradation of mast cells requires direct contact between mast cells and nerve 
terminals, mediated by N-cadherin (N-cad). MMP-24 metalloproteinases prevent mast cell 
degranulation by digesting N-cad. (2) The release of TNF-α and IL-15 by peripheral nerves 
and Schwann cells activates MMP-9 and facilitates the recruitment of macrophages. (3) 
Nociceptive nerve terminals can excrete Substance P (SP) and CGRP substances through 
antidromic activation from neighboring nerve terminal branches. Substance P and CGRP 
increase vasodilation and extravasation of immune cells. Neutral endopeptidase (NEP) inhibits 
nerve inflammation by decreasing substance P and CGRP.24 
 
Figure 2. Immune System Activation and Nociceptors Sensitization in Pain24 
 
b. Central Sensitization 
Primary afferent nociceptive neurons alter the action potential from peripheral nerve to 
the dorsal horn of spinal cord, where synapses occur between first-order and second-order 
neurons. In chronic inflammatory or neuropathic pain, the nociceptive mediator including 
caspase 6 (Casp 6), adenosine triphosphate (ATP), chemokine ligand 2 (CCL2), TNFα, Colony 
Stimulating Factor 1 (CSF-1), and CGRP are released and activate microglia.22 
 
c. Transformation of Peripheral Sensitization into Central Sensitization 
 Immune and glial cells interact with neurons to change pain sensitivity and mediate 




in TTH. In response to injury, immune cells are activated and carried by blood flow to the site 
of injury. These cells not only contribute to protection but also initiate peripheral nociceptive 
sensitivity. Through the synthesis and release of inflammatory mediators and interactions with 
neurotransmitters and their receptors, immune cells, glial cells, and neurons form an integrated 
network that coordinates the immune response and modulates stimulation of the pain 
pathways24. 
The central sensitization process is explained in figure 3: 16,17,18. 
a. Microglia are immune cells in the CNS that play a key role in mediating the central pain 
sensitivity. Primary afferent nociceptive neurons alter the action potential from the 
peripheral nerve to the dorsal horn of spinal cord (the site of synapses of neurons I & II). In 
chronic inflammation, there will be the release of mediators Casp 6, ATP, chemokine 2 
(CCL2) ligands, TNFα, CSF-1, & CGRP which will activate microglia. 
b. Microglia produce inflammatory mediators, namely IL-1β, TNFα, BDNF, PGE2 which are 
sensitive to first-order and second-order neurons and cause central sensitization that 
contributes to chronic pain. T cells also infiltrate the spinal cord, cross-talk with microglia, 
and nociceptive neurons which will strengthen the sensitivity of pain. 
c. After peripheral nerve injury, primary afferent nociceptive neurons release CX3CL1 into 
the spinal cord which causes the following reactions: 
• Induces dorsal horn lobe microglia to produce TNFα 
• Activates astrocytes to produce CCL2 and CXCL1 which will induce changes in the 
spinal cord neurons that cause central sensitization. 
d. In addition, oligodendrocytes produce IL-33 which works in cross-talk with microglia and 






Figure 3. Microglia and T Cells mediate the  Central Sensitization in the Spinal Cord22 
Another concept that has emerged in pain research is that oxidative stress plays an 
important role in chronic pain due to central sensitization. The increasing of Reactive Oxygen 
Species (ROS) levels in the spinal cord along with the increasing of mitochondrial superoxide 
production cause central sensitization and consequently, pain without peripheral nerve injury 
or tissue inflammation. Superoxide can cause peripheral and central sensitization and alter 
nociception, producing hyperalgesia mediated by local and spinal oxidant mechanisms23,25. 
The immune system also reduces sensitivity by producing analgesia and anti-
inflammatory or pro resolution-derived agents from the immune system. The immune system 
role in pain modulation process could be potential targets for the development of analgesic 
drugs and new therapies for managing chronic pain24. 
 
Conclusion 
Tension-type headache is a type of primary headache often complained by patients. Many 
patients ignore the pain and do self-medication which makes the pain to become chronic. The 
focus of pathophysiology is the trigger points nociceptive stimulation that causes peripheral 
and central sensitization. Immune and glial cells play a role in this mechanism. So, a deeper 
understanding and further research are needed to assess its potential as a new therapeutic target 
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